Alessandro Loglio, Ivan Gardini, Massimiliano Conforti, Marco Bartoli, Francesco Silvia, Carmine Coppola, Luchino Chessa, Gianluca Svegliati-Baroni, Laura Schiadà, Ivan Gentile, Biagio Pinchera, Maurizia Rossana Brunetto, Piero Colombatto, Alessio Aghemo, Stella De Nicola, Pierluigi Toniutto, Edoardo Giovanni Giannini, Antonio Colecchia, Dante Romagnoli, Loredana Sarmati, Francesca Romana Ponziani, Filomena Morisco, Calogero Cammà, Giuseppe Cabibbo, Pietro Lampertico, Elisabetta Degasperi, Pietro Invernizzi, Antonio Ciaccio, Francesco Paolo Russo, Antonio Massimo Ippolito, Grazia Anna Niro, Natalia Terreni, Gerardo Nardone, Alba Rocco, Maria D'Antò, David Sacerdoti, Donatella Ieluzzi, Alessia Ciancio, Adriano Pellicelli, Alessandro Federico, Loredana Simone, Vincenzo Messina, Ernesto Claar, Valerio Rosato, Gianpiero D'Offizi, Paolo Caraceni, Paolo Muratori, Cinzia Giaccherini, Stefano Fagiuoli, Mauro Viganò
{"title":"2024年意大利慢性乙型肝炎和德尔塔病毒确诊患者：来自国家真实世界数据库的估计","authors":"Alessandro Loglio, Ivan Gardini, Massimiliano Conforti, Marco Bartoli, Francesco Silvia, Carmine Coppola, Luchino Chessa, Gianluca Svegliati-Baroni, Laura Schiadà, Ivan Gentile, Biagio Pinchera, Maurizia Rossana Brunetto, Piero Colombatto, Alessio Aghemo, Stella De Nicola, Pierluigi Toniutto, Edoardo Giovanni Giannini, Antonio Colecchia, Dante Romagnoli, Loredana Sarmati, Francesca Romana Ponziani, Filomena Morisco, Calogero Cammà, Giuseppe Cabibbo, Pietro Lampertico, Elisabetta Degasperi, Pietro Invernizzi, Antonio Ciaccio, Francesco Paolo Russo, Antonio Massimo Ippolito, Grazia Anna Niro, Natalia Terreni, Gerardo Nardone, Alba Rocco, Maria D'Antò, David Sacerdoti, Donatella Ieluzzi, Alessia Ciancio, Adriano Pellicelli, Alessandro Federico, Loredana Simone, Vincenzo Messina, Ernesto Claar, Valerio Rosato, Gianpiero D'Offizi, Paolo Caraceni, Paolo Muratori, Cinzia Giaccherini, Stefano Fagiuoli, Mauro Viganò","doi":"10.1111/liv.70336","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The number of patients with a healthcare expenditure exemption for CHB (016.070.32) and CHD (016.070.33) was obtained from 21 Regional Health Authorities. To understand how many CHB or CHD patients did not have these specific exemptions, a survey was conducted in 30 Gastroenterology, Hepatology and Infectious Diseases Units across the country.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Health Authorities data reported 67 514 and 5216 subjects with an exemption for CHB and for CHD, respectively. However, among 6775 CHB and 504 CHD patients, only 60.3% and 55.7% of them had the specific exemption, respectively. Based on these results, we estimated 111 960 (95% CI: 109 780–114 240) CHB and 9360 (95% CI: 8690–10 150) CHD patients, with a prevalence of 0.22% and 0.019% of the adult overall population. Moreover, anti-HDV prevalence was 7.7% from this cohort.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study provides a plausible estimate of the current number of adult patients diagnosed with CHB and CHD in Italy and may be considered the basis for decision-making health policies.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70336","citationCount":"0","resultStr":"{\"title\":\"Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database\",\"authors\":\"Alessandro Loglio, Ivan Gardini, Massimiliano Conforti, Marco Bartoli, Francesco Silvia, Carmine Coppola, Luchino Chessa, Gianluca Svegliati-Baroni, Laura Schiadà, Ivan Gentile, Biagio Pinchera, Maurizia Rossana Brunetto, Piero Colombatto, Alessio Aghemo, Stella De Nicola, Pierluigi Toniutto, Edoardo Giovanni Giannini, Antonio Colecchia, Dante Romagnoli, Loredana Sarmati, Francesca Romana Ponziani, Filomena Morisco, Calogero Cammà, Giuseppe Cabibbo, Pietro Lampertico, Elisabetta Degasperi, Pietro Invernizzi, Antonio Ciaccio, Francesco Paolo Russo, Antonio Massimo Ippolito, Grazia Anna Niro, Natalia Terreni, Gerardo Nardone, Alba Rocco, Maria D'Antò, David Sacerdoti, Donatella Ieluzzi, Alessia Ciancio, Adriano Pellicelli, Alessandro Federico, Loredana Simone, Vincenzo Messina, Ernesto Claar, Valerio Rosato, Gianpiero D'Offizi, Paolo Caraceni, Paolo Muratori, Cinzia Giaccherini, Stefano Fagiuoli, Mauro Viganò\",\"doi\":\"10.1111/liv.70336\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Aims</h3>\\n \\n <p>Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The number of patients with a healthcare expenditure exemption for CHB (016.070.32) and CHD (016.070.33) was obtained from 21 Regional Health Authorities. To understand how many CHB or CHD patients did not have these specific exemptions, a survey was conducted in 30 Gastroenterology, Hepatology and Infectious Diseases Units across the country.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Health Authorities data reported 67 514 and 5216 subjects with an exemption for CHB and for CHD, respectively. However, among 6775 CHB and 504 CHD patients, only 60.3% and 55.7% of them had the specific exemption, respectively. Based on these results, we estimated 111 960 (95% CI: 109 780–114 240) CHB and 9360 (95% CI: 8690–10 150) CHD patients, with a prevalence of 0.22% and 0.019% of the adult overall population. Moreover, anti-HDV prevalence was 7.7% from this cohort.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Our study provides a plausible estimate of the current number of adult patients diagnosed with CHB and CHD in Italy and may be considered the basis for decision-making health policies.</p>\\n </section>\\n </div>\",\"PeriodicalId\":18101,\"journal\":{\"name\":\"Liver International\",\"volume\":\"45 10\",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70336\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/liv.70336\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70336","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database
Background and Aims
Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.
Methods
The number of patients with a healthcare expenditure exemption for CHB (016.070.32) and CHD (016.070.33) was obtained from 21 Regional Health Authorities. To understand how many CHB or CHD patients did not have these specific exemptions, a survey was conducted in 30 Gastroenterology, Hepatology and Infectious Diseases Units across the country.
Results
Health Authorities data reported 67 514 and 5216 subjects with an exemption for CHB and for CHD, respectively. However, among 6775 CHB and 504 CHD patients, only 60.3% and 55.7% of them had the specific exemption, respectively. Based on these results, we estimated 111 960 (95% CI: 109 780–114 240) CHB and 9360 (95% CI: 8690–10 150) CHD patients, with a prevalence of 0.22% and 0.019% of the adult overall population. Moreover, anti-HDV prevalence was 7.7% from this cohort.
Conclusion
Our study provides a plausible estimate of the current number of adult patients diagnosed with CHB and CHD in Italy and may be considered the basis for decision-making health policies.
期刊介绍：
Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
